Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van het geneesmiddel genaamd Abrocitinib bij kinderen van 6 tot minder dan 12 jaar met matig tot ernstig eczeem

24 september 2026 bijgewerkt door: Pfizer

Een 16-weken durende, multicenter, interventionele, fase 3, gerandomiseerde, dubbelblinde, placebo-gecontroleerd, parallelle groepsstudie om de werkzaamheid en veiligheid van schouderbeurt te onderzoeken bij kinderen van 6 tot minder dan 12 jaar met matige tot ernstige atopische dermatitis

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Studie Overzicht

Toestand

Werving

Conditie

Gedetailleerde beschrijving

Different questionnaires will be used to find out how the participant's eczema is doing during the research study. An electronic diary, which looks like a cellular phone, will be used to collect the questionnaire information and other research study-related information. It will also be used to remind participants to take the test medicine each day and to fill out the questionnaires. Participants will also be asked to wear something on their wrist that looks like a children's wristwatch so we can know when they are scratching their skin because of their atopic dermatitis. Laboratory tests, physical examinations and vital signs (height, weight, temperature, blood pressure and heart rate) will be conducted before and during the research study to monitor your child's health. Participants will need to come to the clinic for research study visits and at other times during the research study, the research study doctor or nurse will call the participants to find out the participant is doing.

Studietype

Ingrijpend

Inschrijving (Geschat)

150

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Shanghai, China, 200062
        • Werving
        • Shanghai Children's Hospital
      • Shanghai, China, 200092
        • Werving
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100045
        • Werving
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen, Guangdong, China, 518026
        • Werving
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha, Hunan, China, 410007
        • Werving
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, China, 330000
        • Werving
        • Dermatology Hospital of Jiangxi Province
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Werving
        • Shanghai Children's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310009
        • Werving
        • Hangzhou Third People's Hospital
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Duitsland, 48149
        • Werving
        • Universitätsklinikum Münster
    • Saxony
      • Dresden, Saxony, Duitsland, 01307
        • Werving
        • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
      • Pécs, Hongarije, 7622
        • Werving
        • University of Pecs
    • Baranya
      • Pécs, Baranya, Hongarije, 7632
        • Werving
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba, Bekes County, Hongarije, 5600
        • Werving
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged, Csongrád-csanád, Hongarije, 6720
        • Werving
        • Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika
    • Pest County
      • Budapest, Pest County, Hongarije, 1033
        • Werving
        • Clinexpert Kft.
      • Fukuoka, Japan, 811-1394
        • Werving
        • Fukuoka National Hospital
      • Fukuoka, Japan, 819-0042
        • Werving
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 220-6208
        • Werving
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai, Osaka, Japan, 593-8324
        • Werving
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku, Tokyo, Japan, 157-0066
        • Werving
        • Sasamoto Children's Clinic
      • Chihuahua City, Mexico, 31238
        • Werving
        • Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)
    • Mexico City
      • Mexico City, Mexico City, Mexico, 06720
        • Werving
        • Hospital Infantil de México Federico Gómez
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64718
        • Werving
        • Eukarya Pharmasite S.C.
    • Veracruz
      • Veracruz, Veracruz, Mexico, 91900
        • Werving
        • Arke SMO S.A. de C.V.
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 30-002
        • Werving
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-573
        • Werving
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-625
        • Werving
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, Polen, 41-500
        • Werving
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
      • Katowice, Silesian Voivodeship, Polen, 40-611
        • Werving
        • Centrum Medyczne Angelius Provita
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 90-436
        • Werving
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polen, 27-400
        • Werving
        • Dermedic Jacek Zdybski
      • Zaragoza, Spanje, 50009
        • Werving
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela, A Coruña [LA Coruña], Spanje, 15706
        • Werving
        • CHUS - Hospital Clinico Universitario
    • Barcelona [barcelona]
      • Granollers, Barcelona [barcelona], Spanje, 08402
        • Werving
        • Hospital General de Granollers
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35244
        • Werving
        • Cahaba Dermatology & Skin Health Center, LLC
    • Arkansas
      • North Little Rock, Arkansas, Verenigde Staten, 72117
        • Werving
        • Arkansas Research Trials
    • California
      • San Diego, California, Verenigde Staten, 92123
        • Werving
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego, California, Verenigde Staten, 92123
        • Werving
        • University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32256
        • Werving
        • Solutions Through Advanced Research
    • Idaho
      • Meridian, Idaho, Verenigde Staten, 83646
        • Werving
        • Ada West Research
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46250
        • Werving
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63104
        • Werving
        • Saint Louis University - Department of Dermatology
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina - Department of Dermatology
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina - Walton Research Building
      • Greenville, South Carolina, Verenigde Staten, 29607
        • Werving
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio, Texas, Verenigde Staten, 78235
        • Werving
        • Texas Dermatology and Laser Specialists

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar tot 11 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria Children aged 6 to <12 years at the time of informed consent/assent.

• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Disease Characteristics:

Participants who meet all of the following AD criteria:

  • A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
  • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
  • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy

Other Inclusion Criteria:

Body weight ≥15 kg

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

Have any of the following medical conditions:

  • Infections:

    • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
    • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
    • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
    • Infection with HIV, hepatitis B, and/or hepatitis C
    • Evidence of active TB or inadequately treated latent TB.
  • Skin Conditions:

    - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

  • Other Conditions:

    • Documented history of skeletal dysplasia.
    • Documented history of retinal detachment.
    • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
    • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
    • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
    • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

Prior/Concomitant Therapy:

Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.

Prior/Concurrent Clinical Study Experience:

Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Abrocitinib

Abrocitinib administered as liquid oral suspension.

Abrocitinib administered as liquid oral suspension.

Andere namen:
  • PF-04965842
Placebo-vergelijker: Matching Placebo

Placebo administered as liquid oral suspension.

Placebo administered as liquid oral suspension.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
Tijdsspanne: At week 12

The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
Tijdsspanne: At week 12

The difference in proportion of responders based on EASI-75 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline (CFB) in the Worst Itch Numerical Rating Scale (WI-NRS) at Week 2
Tijdsspanne: At week 2

The difference in mean CFB in WI-NRS total score at Week 2 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 2
Response based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12
Tijdsspanne: At week 12

The difference in proportion of responders based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving WI-NRS <2 at Week 12
Tijdsspanne: At week 12

The difference in proportion of responders based on achieving WI-NRS <2 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Pfizer CT.gov Call Center, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 juli 2025

Primaire voltooiing (Geschat)

2 mei 2027

Studie voltooiing (Geschat)

2 mei 2027

Studieregistratiedata

Eerst ingediend

29 januari 2025

Eerst ingediend dat voldeed aan de QC-criteria

29 januari 2025

Eerst geplaatst (Werkelijk)

4 februari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • B7451023
  • 2023-509121-51-00 (Register-ID: CTIS (EU))
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren